UPDATE : Friday, December 14, 2018
HOME Pharma
Novo Nordisk launches diabetes treatment Ryzodeg in Korea
  • By Marian Chu
  • Published 2017.11.15 09:51
  • Updated 2017.11.15 14:53
  • comments 0

Novo Nordisk Korea has launched diabetes treatment Ryzodeg in the Korean market. Ryzodeg is the first combination insulin injection made from a 70-30 ratio of two types of insulin -- insulin degludec and insulin aspart.

The 70-30 ratio of the “long-acting” insulin degludec (that controls blood glucose between meals), and the “rapid-acting” insulin aspart (that controls mealtime excursions of glucose) helps maintain stable control of glucose levels, company officials said at a news conference in Seoul Tuesday.

Ole Mølskov Bech, Novo Nordisk’s senior vice president of the Japan and Korea region, explains the company’s new diabetes treatment, during a news conference in Seoul Tuesday.

The injection, administered twice a day with meals, can be used by those older than two years old to those over 65, and even by those with kidney and liver complications, they said.

“Ryzodeg is now coming to Korea. It is the 14th country in the world where the product is available,” said Ole Mølskov Bech, Novo Nordisk’s senior vice president of the Japan and Korea region. “We are proud to bring this innovation to Korea quickly compared to other countries.”

The drug gained approval in more than 80 countries and won national coverage in September, according to Novo Nordisk Korea.

The drug demonstrated efficacy and safety in 2,414 patients with type-1 and type-2 diabetes in five key studies, with one phase 3a study – BOOST Intensify Premix I – proving the non-inferiority of the injection compared to NovoMix (BIAsp 30), the company said.

Roopa Mehta from the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirá in Mexico presented trial findings at the conference.

Results showed a statistically significant lowering of overall hypoglycemic incidence by 32 percent and a lowering of nocturnal hypoglycemia by 73 percent when compared to NovoMix 30, Mehta said. It also lowered fasting blood glucose (FPG) significantly by 20.52 mg/dL, she added.

“What’s impressive about this insulin is we need to use less insulin – an 11 percent lower dose – compared to conventional insulin, which is statistically significant,” Mehta said. “We in Mexico had this (therapy) for at least three years now. I think it is vital insulin for the diabetic population.”


<© Korea Biomedical Review, All rights reserved.>

Other articles by Marian Chu
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top